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Introduction: The use of peripheral hematopoietic progenitor cells (HPCs) is the cell choice
in  autologous transplantation. The classic dose of granulocyte-colony stimulating factor (G-
CSF)  for mobilization is a single daily dose of 10 g/kg of patient body weight. There is a
theory  that higher doses of granulocyte-colony stimulating factor applied twice daily could
increase the number of CD34+ cells collected in fewer leukapheresis procedures.
Objective: The aim of this study was to compare a fractionated dose of 15 g G-CSF/kg of
body  weight and the conventional dose of granulocyte-colony stimulating factor in respect
to  the number of leukapheresis procedures required to achieve a minimum collection of
3  × 106 CD34+ cells/kg body weight.
Methods: Patients were divided into two groups: Group 10 – patients who received a single
daily dose of 10 g G-CSF/kg body weight and Group 15 – patients who received a fractioned
dose  of 15 g G-CSF/kg body weight daily. The leukapheresis procedure was carried out in an
automated cell separator. The autologous transplantation was carried out when a minimum
number of 3 × 106 CD34+ cells/kg body weight was achieved.
Results: Group 10 comprised 39 patients and Group 15 comprised 26 patients. A total of 146
apheresis procedures were performed: 110 (75.3%) for Group 10 and 36 (24.7%) for Group
15.  For Group 10, a median of three (range: 1–7) leukapheresis procedures and a mean
6 +of  8.89 × 10 CD34 cells/kg body weight (±9.59) were collected whereas for Group 15 the
corresponding values were one (range: 1–3) and 5.29 × 106 cells/kg body weight (±4.95). A sta-
tistically signiﬁcant difference was found in relation to the number of apheresis procedures
(p-value <0.0001).
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Conclusions: To collect a minimum target of 3 × 106 CD34+ cells/kg body weight, the admin-
istration of a fractionated dose of 15 g G-CSF/kg body weight signiﬁcantly decreased the
number of leukapheresis procedures performed.
©  2015 Associac¸ão Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published
by Elsevier Editora Ltda. All rights reserved.
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he autologous transplantation of peripheral hematopoietic
rogenitor cells (HPCs) is widely used to treat solid tumors
nd lymphomas in children, adolescents and young adults.1–3
ince the end of the 1980s the use of leukapheresis has
een the most used method to harvest cells for autologous
ransplantation as it is considered to be effective and safe, pro-
oting a faster hematopoietic recovery and posing less risk to
he patient (no general anesthesia and no anemia). As a con-
equence, this method is associated with lower cost and there
s less risk of contamination of the graft by neoplastic cells
ompared to bone marrow.4 According to the Center for Inter-
ational Blood and Marrow Transplant Research (CIBMTR),5
round 32,000 transplants were carried out in the last decade
ith, in most cases, the cell source being peripheral HPCs.5 In
1% of cases where a bone marrow transplant is needed in the
hild population of the US, peripheral HPCs are harvested with
he most common reasons for treatment being lymphomas
nd solid tumors.5
Myelosuppressive chemotherapy or high doses of
hemotherapy in association with granulocyte-colony
timulating factor (G-CSF) has been successfully used in
he mobilization of peripheral HPCs with a reduction of
ontamination by neoplastic cells.6,7 These treatments are
afe and well tolerated with a large capacity for mobilization
nd action against neoplastic cells. Cyclophosphamide (CY),
lone or in combination with other agents, is the most com-
only used chemotherapy drug8 although other regimens
uch as the ifosfamide, carboplatin and etoposide (ICE) and
examethasone, adriamycin and cisplatin regimens (DHAP)
re also employed.9–11 However, the most effective regimen,
ith the most suitable intensity of mobilization, remains to
e deﬁned.4,12
G-CSF is the most potent cytokine available4 and the one
ost commonly used for the mobilization of peripheral HPCs.5
-CSF has low toxicity and is well tolerated. The most com-
on  side effect is mild bone pain, beginning after two or
hree applications,13 however, few patients need to reduce
he dose or discontinue treatment.4 In autologous transplan-
ation, the classic G-CSF dose for mobilization is 10 g/kg of
atient body weight (bw) via subcutaneous administration
nce a day.12,14 Some studies have shown that larger doses
f G-CSF and fractionated doses given in two daily appli-
ations increase the number of CD34+ cells collected with
 lower number of leukapheresis procedures.15,16 Moreover,
n patients whose mobilization failed with the conventional
ose of G-CSF, an increase in the dose to 12.5–50 g/kg
w/day can be successful.6,17 Subcutaneous G-CSF adminis-
ration achieves a maximum serum level within 2–8 h afterapplication with a half-life of 3–4 h.18 Thus, a single daily appli-
cation may not be optimal.18
The recognized method of harvesting peripheral HPCs is
large-volume leukapheresis (LVL).5 With current technology,
leukapheresis can be carried out in very young children with
low weights (<10 kg), allowing a sufﬁcient number of CD34+
cells to be collected for complete bone marrow recovery after
high doses of safely applied chemotherapy.18–20
The determination of the time at which to begin leuka-
pheresis is based on several factors, such as the kinetics of
leukocyte recovery after myelosuppressive chemotherapy, the
peripheral platelet count, the absolute number of leukocytes
in the peripheral blood and the concentration of circulating
peripheral CD34+ cells.21–23 The most commonly applied crite-
ria are an absolute leukocyte count ≥1 × 103 cells/L and a
CD34+ cell concentration ≥10 cells/L.22,23
The increased circulation of peripheral CD34+ cells after
mobilization lasts a short time and thus it is fundamental that
apheresis is carried out during this period in order to collect
a sufﬁcient number of CD34+ cells. The peak in CD34+ cells is
reached after the leukocyte nadir in the recovery from aplasia
caused by myelosuppressive chemotherapy.24 The moment at
which there is a sufﬁcient quantity of CD34+ cells for col-
lection by apheresis is when the peripheral leukocyte count
reaches ≥1 × 103 cells/L after recovery from the nadir.25 Con-
sequently, it is proposed that the peripheral HSC collection
should begin when the total leukocyte count reaches ≥1 × 103
cells/L after the nadir and the concentration of CD34+ cells in
peripheral blood is ≥10 cells/L.22,23 One of the best indicators
of hematopoietic recovery in autologous transplantation is the
amount of infused CD34+ cells/kg bw.16 The minimum values
for the acceptable number of CD34+ cells to achieve a fast, safe
and effective engraftment after autologous transplantation is
between 2 and 5 × 106/kg bw.4,26,27
In order to obtain the ideal number of CD34+ cells collected
for autologous transplantation in children, this study inves-
tigates whether the use of G-CSF at a fractionated dose of
15 g/kg bw would reduce the number of leukapheresis proce-
dures required to achieve a minimum number of CD34+ cells
of 3 × 106/kg bw and compares the results with those obtained
using the conventional single dose of 10 g/kg bw G-CSF.
Methods
This ambispective study was carried out at a single institu-
tion. The eligibility criteria for participation in the study were:
under 24-year-old patients recommended for autologous
transplantation diagnosed with solid tumors or lymphomas,
and treated at the Centro Infantil Boldrini (Boldrini Children’s
Center) with up to four chemotherapy treatment regimens,
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Table 1 – Characteristics of patients in each group.
Variable Group 10
n  = 39
Group 15
n  = 26
Gender – n (%)
Male 23 (59) 13 (50)
Female 16 (41) 13 (50)
Race – n (%)
White 32 (82) 20 (77)
Non-White – n (%) 7 (18) 6 (23)
Age – median (range) 12 (1–20) 6 (1–22)
Diagnosis – n (%)
HL 19 2
NHL 6 2
Solid tumor 14 22
Prior CT – median (range) 2 (1–3) 2 (1–4)
HL: Hodgkin lymphoma; NHL: Non-Hodgkin lymphoma; Solid
complete blood count and the percentage of CD34 cells wastumor: Germ cell tumor, Neuroblastoma, Ewing sarcoma and
Medulloblastoma; CT: Chemotherapy treatment
and mobilized with chemotherapy and G-CSF. The study was
approved by the appropriate ethics committee and informed
consent forms were signed by the patients or their guardians.
The patients were divided into two groups: Group 10 was
comprised of patients who  received a single daily dose of 10 g
G-CSF/kg bw between December 1998 and December 2008 and
Group 15 was comprised of patients who received a fraction-
ated daily dose (deﬁned below in the section on G-CSF) of 15 g
G-CSF/kg bw between August 2010 and April 2013. The patient
characteristics are detailed in Table 1.
Mobilization  chemotherapy
The mobilization chemotherapy regimens (MCR) adminis-
tered using cyclophosphamide (Regimen A) included CY
(cyclophosphamide 4 g/m2/day × 1 day), Topo/CY (topote-
can 0.75 mg/m2/day × 5 days and cyclophosphamide
250 mg/m2/day × 5 days), Cy/Vp-16 (cyclophosphamide
4–7 g/m2/day × 1 day and etoposide 4 g/m2/day × 1 day),
Cy/MTX/VP-16 (cyclophosphamide 4–7 g/m2/day × 1 day,
methotrexate 8 g/m2/day × 1 day and etoposide 4 g/m2/day × 1
day) and Cy/Adria (cyclophosphamide 2.4 g/m2/day × 2
days and adriamycin 20 mg/m2/day × 3 days) and those
without cyclophosphamide (Regimen B) were ICE (ifos-
famide 3 g/m2/day × 3 days, carboplatin 500 mg/m2/day × 2
days and etoposide 150 mg/m2/day × 3 days), TIP (taxol
175 mg/m2/day × 1 day, ifosfamide 1.2 g/m2/day × 5 days
and cisplatin 20 mg/m2/day × 5 days), IFO/Vp-16 (ifos-
famide 2.5 g/m2/day × 5 days, cisplatin 40 mg/m2/day × 4
days, doxorubicin 10 mg/m2/day × 4 days and etopo-
side 125 mg/m2/day × 4 days), DHAP (dexamethasone
40 mg/day × 4 days, cytarabine: 400 mg/m2/day × 1 day and
cisplatin 100 mg/m2/day × 1 day).
Granulocyte-colony  stimulating  factorG-CSF (Granulokine®; Roche, SP, Brazil/Leucin®; Bergamo, SP,
Brazil/Filgrastine®; Blausiegel, SP, Brazil) is the most potent
cytokine available and is the most used in the mobilization 2 0 1 5;3  7(3):160–166
of peripheral HPCs5,6 as it has synergistic actions with other
growth factors which induce mobilization. In this study the
administration of G-CSF was started one day after the end
of the MCR. The G-CSF was administered subcutaneously at
6:00 a.m. as a single dose for Group 10 (10 g/kg bw)  and as
two doses for Group 15, 10 g/kg bw at 6:00 a.m. and 5 g/kg
bw at 6:00 p.m. This was continued daily for both groups until
successful collection of the minimum amount of 3 × 106 CD34+
cells/kg bw or until the characterization of lack of mobilization
was determined by an unsuccessful collection.
Vascular  access
A non-completely implantable two-way central venous
catheter was introduced into all patients in order to carry out
the LVL.
Large-volume  leukapheresis
Leukapheresis was carried out in an automatic continuous
ﬂow cell separator with the anticoagulant citrate dextrose
solution (ACD-A – CS3000 plus®; Cobe-spectra®; Com.tec®).
The ﬁrst LVL procedure for Group 15 was carried out after the
MCR with ≥1 × 103 cells/L of leukocytes and ≥10 cells/L of
CD34+ in the peripheral blood and for Group 10 with ≥1 × 103
cells/L of leukocytes. Patients who weighed <20 kg received
priming with irradiated and ﬁltered packed red blood cells
(PRBCs) (20 mL/kg bw). During the LVL all patients received
intravenous (IV) replacement of calcium, sodium, potassium
and magnesium and were under continuous monitoring. Four
blood volumes were processed per leukapheresis procedure
and if symptoms and/or signs of hypocalcemia related to
the anticoagulant used in the cell separator system were
observed, a dose of 0.2 mL/kg bw of 10% calcium gluconate
was administered intravenously. All patients who  did not
reach the minimum number of CD34+ cells (3 × 106/kg bw)  in
the ﬁrst leukapheresis procedure were submitted to another
procedure on the following day regardless of the number of
leukocytes and CD34+ cells in the peripheral blood. A limit of
two more  leukapheresis procedures was set for Group 15 but
with no limit in the number of procedures for Group 10.
Complete  blood  count  after  large-volume  leukapheresis
A complete blood count was obtained after each LVL pro-
cedure. A prophylactic transfusion was carried out with an
irradiated and ﬁltered platelet concentrate (PC) if the number
of platelets in the peripheral blood was <10 × 103 cells/L and
irradiated and ﬁltered PRBC transfusion if the hemoglobin (Hb)
was <8.0 g/dL.
Peripheral  hematopoietic  progenitor  cell  analysis
The nucleate cell (NC) count for the leukapheresis product was
carried out using the automatic counter used to obtain the
+determined by ﬂow cytometry using the standard Sutherland
Technique.28 To carry out the autologous transplantation the
number of CD34+ cells was deﬁned as 3 × 106/kg bw.
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Table 2 – Mobilization chemotherapy regimens (MCR).
MCR Group 10 Group 15 p-value
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S
A
a
a
t
m
p
(
R
F
D
p
w
i
r
1
l
a
d
m
g
f
w
(
G
v
r
t
l
r
T
p
p
d
m
d
a
5
d
1
d
p
d
m
d
pheresis procedure (range: 1–3) and medians of 10.17 × 108/kg
bw NCs (range: 1.22–37.0) and 5.29 × 106 CD34+ cells/kg bw
(range: 0.6–27.8) were collected (Figures 1 and 2). The median
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tatistical  analysis
 descriptive analysis of all variables involved was carried out
nd then the Chi squared or Fisher exact tests were applied
s appropriate to the categorical variables while the Student
-test was applied to the continuous variables to compare the
eans of Groups 10 and 15. Statistical signiﬁcance was set for
-values <0.05. The Statistical Package for the Social Sciences
SPSS) version 21.0 was use in all analyses.
esults
ifty-three patients received 10 g G-CSF/kg bw between
ecember 1998 and December 2008 (Group 10). Fourteen
atients were excluded from the analysis: eight mobilized only
ith G-CSF, one was 29 years of age and mobilization failed
n ﬁve cases. Between August 2010 and April 2013, 35 patients
eceived a fractionated dose of 15 g G-CSF/kg bw daily (Group
5) with nine being excluded from the analysis due to mobi-
ization failure.
Of the 65 patients analyzed, 55.4% were male, the median
ge was ten years (1–22), 80% were white and 55.4% were
iagnosed with solid tumors. The median number of pre-
obilization chemotherapy cycles received was two for both
roups; varying from one to three for Group 10 and one to four
or Group 15, with no statistically signiﬁcant difference, and
ith no inﬂuence on the number of CD34+ cells collected.
With regard to the MCR, Regimen A was used in 23/39
59%) of cases of Group 10 and 22/26 (84%) of cases of
roup 15 resulting in a statistically signiﬁcant difference (p-
alue = 0.03) (Table 2). However, no difference in the leukocyte
ecovery time (≥1 × 103 cells/L) was observed between the
wo regimens and the MCR  did not inﬂuence the number of
eukapheresis procedures per group and no patients had MCR-
elated complications.
Regimen A: CY (cyclophosphamide 4 g/m2/day × 1 day),
opo/CY (topotecan 0.75 mg/m2/day × 5 days and cyclophos-
hamide 250 mg/m2/day × 5 days), Cy/Vp-16 (cyclophos-
hamide 4–7 g/m2/day × 1 day and etoposide 4 g/m2/day × 1
ay), Cy/MTX/Vp-16 (cyclophosphamide 4–7 g/m2/day × 1 day,
ethotrexate 8 g/m2/day × 1 day and etoposide 4 g/m2/day × 1
ay) and Cy/Adria (cyclophosphamide 2.4 g/m2/day × 2 days
nd adriamycin 20 mg/m2/day × 3 days).
Regimen B: ICE (ifosfamide 3 g/m2/day × 3 days, carboplatin
00 mg/m2/day × 2 days and etoposide 150 mg/m2/day × 3
ays), TIP (taxol 175 mg/m2/day × 1 day, ifosfamide
.2 g/m2/day × 5 days and cisplatin 20 mg/m2/day × 5
ays/), IFO/Vp-16 (ifosfamide 2.5 g/m2/day × 5 days, cis-
latin 40 mg/m2/day × 4 days, doxorubicin 10 mg/m2/day × 4
2ays and etoposide 125 mg/m /day × 4 days), DHAP (dexa-
ethasone 40 mg/day × 4 days, cytarabine: 400 mg/m2/day × 1
ay and cisplatin 100 mg/m2/day × 1 day). 1 5;3  7(3):160–166 163
All patients showed good tolerance to G-CSF administra-
tion; no applications were suspended or reduced in either
group and only ﬁve (13%) patients of Group 10 and two (7%)
patients of Group 15 reported mild bone pain.
The median number of pre-leukapheresis leukocytes was
14.4 × 103 cells/L (range: 0.9–50.3) for Group 10 and 22.3 × 103
cells/L (range: 3.0–73.9) for Group 15. The median concen-
tration of peripheral CD34+ cells was 27.9 per L (range:
1.10–135.0) for Group 10 and 29.5 cells per L (range: 8.0–90.0)
for Group 15, with no statistically signiﬁcant difference
between values. No patients had complications during the
leukapheresis procedure in either group; no hypovolemia was
observed in children who weighed <20 kg and only two (5%)
patients in Group 10 reported mild paresthesia related to the
use of the anticoagulant. Thirty-two patients, 15 (38%) from
Group 10 and 17 (65%) from Group 15, had platelet counts
<50 × 103 cells/L  during the pre-leukapheresis period. How-
ever, no type of bleeding occurred and only one (3%) patient of
Group 15 received post-leukapheresis irradiated and ﬁltered
PC. None of the patients from either group received a trans-
fusion of irradiated and ﬁltered PRBCs after leukapheresis.
Three (7%) cases in Group 10 and 11 (42%) cases in Group 15
received priming of irradiated and ﬁltered PRBCs during the
leukapheresis procedure.
A total of 146 leukapheresis procedures were carried out,
110 in Group 10 and 36 in Group 15, with an average dura-
tion of 4 h (±2); the second leukapheresis procedure of one
patient in Group 15 was interrupted half-way through the
procedure due to malfunctioning of the cell separator; there
was malfunctioning of the catheter in four patients. More-
over, one patient of Group 10 and one of Group 15 had
prolonged LVL times and it was not possible to collect the
minimum number of CD34+ cells in two cases of Group
15. A median of three (range: 1–7) leukapheresis procedures
were performed for Group 10 with medians of 7.22 × 108/kg
bw (range: 1.28–20.70) and 8.89 × 106/kg bw (range: 0.3–45)
of nucleated cells (NCs) and CD34+ cells, respectively being
collected. In Group 15 there was a median of one leuka-10µg/kg/w of G-CSF 15 µg/kg/w of G-CSF
Figure 1 – Total number of collected nucleated cells.
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10µg/kg/w of G-CSF 15 µg/kg/w of G-CSFFigure 3 – Numbers of leukapheresis.
number of days of leukocyte recovery was eight (range: 0–18)
for Group 10 and ten (range: 2–13) for Group 15 (p-value = 0.15).
Thus, statistically signiﬁcant differences between groups were
observed for the number of leukapheresis procedures (p-value
<0.0001) (Figure 3) and the number of CD34+ cells collected (p-
value = 0.02), while the total NC count resulted in a favorable
tendency toward Group 15 (p-value = 0.06).
A statistically signiﬁcant distribution was observed on
comparing groups in respect to pre-apheresis peripheral
Table 3 – Collected CD34+ cells versus pre-leukapheresis
peripheral CD34+ cell count.
Collected cells
(×106 cells/L/kg bw)
Pre-leukapheresis CD34+ count
(×106 cells/L/kg bw)
p-value
<10 ≥10
<3.0 × 106 9 22 0.04
≥3.0 × 106 3 31
Bw: body weight. 2 0 1 5;3  7(3):160–166
CD34+ cells (≥10 or <10 cells/L) and the number of CD34+
cells collected (≥3.0 or <3.0 × 106 cells/L) (Table 3).
Discussion
Some authors23,29 suggest that the number of pre-MCR
received negatively inﬂuences the number of CD34+ cells col-
lected, which was not observed in this study. The MCR  used in
this study did not cause complications, even in patients tak-
ing high doses of cyclophosphamide (4–7 g/m2). It is known
that each patient responds in a distinct way to mobilization
and that other parameters may have a negative effect, such as
the time between the diagnosis and harvest, previous irradia-
tion, thrombocytopenia at the time of mobilization and many
other factors cited in the literature.5,23,28,29 Consequently, in
this study it was not possible to deﬁne the best mobilization
chemotherapy regimen as is reported in the literature.4,12
The administration of G-CSF was well tolerated as the
only side effect reported by the patients was mild bone pain
in 10% of the cases which is the side effect most com-
monly reported.13 Priming with irradiated and ﬁltered PRBCs
of children weighing below 20 kg allowed the LVL procedure
to be safely carried out without complications. In the two
cases of mild anticoagulant-related paresthesia, the condition
was reverted using intravenous calcium gluconate. Problems
related to the non-completely implanted two-way catheter
were few with only around 6% of the catheters malfunctioning,
a lower rate than reported in the literature.22,29
With the exception of one leukapheresis procedure (1/146),
which was interrupted half way through, the cell separators
functioned acceptably and there was no need for technical
adjustment in the other leukapheresis procedures. The time
of leukapheresis was well tolerated including by under 5-year-
old children as there were no complaints from patients who
experienced prolonged processing times; these patients did
not show signs or symptoms of anticoagulant-related hypocal-
cemia.
The absolute peripheral leukocyte count (≥1 × cells/L) and
CD34+ cell concentration (≥10 cells/L) were found to be good
parameters to start leukapheresis, in particular the periph-
eral CD34+ cell concentration (≥10 cells/L), even though this
parameter cannot be used for all patients.
In Group 15, the fractionated application of 15 g G-
CSF/kg bw decreased the number of leukapheresis procedures
required to obtain the minimum number of CD34+ cells estab-
lished, and although a maximum of three leukapheresis
procedures was deﬁned for this group, the median was one
procedure. A factor which may appear to be a limitation in this
study, as the maximum number of leukapheresis procedures
for this group was established at three a priori, and which was
in fact observed, was that the fractionated dose led to the min-
imum number of CD34+ cells being achieved without the need
for further collections, that is, regardless of the study design,
this group did not require further leukapheresis procedures.
Only one patient underwent three leukapheresis procedures,
while around 65% achieved the target after only one proce-
dure. Consequently, these results indicate that the efﬁciency
of the fractionated dose needs to be evaluated in greater
detail.
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onclusions
his study demonstrated that the mobilization and collection
f peripheral HPCs in children is viable and safe. The absolute
eripheral leukocyte count (≥1 × 103 cells/L) and CD34+ cell
oncentration (≥ 10 cells/L), when used together, are good
arameters to indicate the start of leukapheresis. The fraction-
ted application of 15 g G-CSF/kg bw signiﬁcantly reduced
he number of leukapheresis procedures needed to collect a
inimum of 3 × 106 cells/kg bw CD34+ cells.
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